JP2013508391A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508391A5
JP2013508391A5 JP2012535346A JP2012535346A JP2013508391A5 JP 2013508391 A5 JP2013508391 A5 JP 2013508391A5 JP 2012535346 A JP2012535346 A JP 2012535346A JP 2012535346 A JP2012535346 A JP 2012535346A JP 2013508391 A5 JP2013508391 A5 JP 2013508391A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012535346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/053433 external-priority patent/WO2011050104A2/en
Publication of JP2013508391A publication Critical patent/JP2013508391A/ja
Publication of JP2013508391A5 publication Critical patent/JP2013508391A5/ja
Pending legal-status Critical Current

Links

JP2012535346A 2009-10-20 2010-10-20 体重増加を予防するために抗ｃｄ３抗体を使用する方法 Pending JP2013508391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25347409P 2009-10-20 2009-10-20
US61/253,474 2009-10-20
PCT/US2010/053433 WO2011050104A2 (en) 2009-10-20 2010-10-20 Methods of using anti-cd3 antibodies to prevent weight gain

Publications (2)

Publication Number Publication Date
JP2013508391A JP2013508391A (ja) 2013-03-07
JP2013508391A5 true JP2013508391A5 (enExample) 2013-12-05

Family

ID=43900946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535346A Pending JP2013508391A (ja) 2009-10-20 2010-10-20 体重増加を予防するために抗ｃｄ３抗体を使用する方法

Country Status (5)

Country Link
US (1) US20130171142A1 (enExample)
EP (1) EP2490719A4 (enExample)
JP (1) JP2013508391A (enExample)
CA (1) CA2778331A1 (enExample)
WO (1) WO2011050104A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3504241B1 (en) * 2016-08-29 2024-05-15 Tiziana Life Sciences PLC Anti-cd3 antibody formulations
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8064994B2 (en) * 2003-01-14 2011-11-22 The United States Of America As Represented By The Department Of Veterans Affairs Cervical vagal stimulation induced weight loss
WO2006096565A2 (en) * 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与

Similar Documents

Publication Publication Date Title
JP2010229134A5 (enExample)
JP2011509245A5 (enExample)
TWI373343B (en) Antibodies that bind human interleukin-18 and methods of making and using
HRP20170815T1 (hr) Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe
JP2009500457A5 (enExample)
JP2020500542A5 (enExample)
JP2020023523A5 (enExample)
JP2008516970A5 (enExample)
JP2011520898A5 (enExample)
JP2013508392A5 (enExample)
JP2017522903A5 (enExample)
JP2009502171A5 (enExample)
JP2005526501A5 (enExample)
US10875916B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F
JP2010500005A5 (enExample)
JP2010526028A5 (enExample)
JP2018502060A5 (enExample)
JP2012139223A5 (enExample)
WO2007033230A2 (en) Anti-cd3 antibody formulations
JP2018500014A5 (enExample)
CN108367075A (zh) 4-1bb结合蛋白及其用途
JP2018537962A5 (enExample)
JP2014039548A5 (enExample)
JP2020002172A5 (enExample)
JP2009225799A5 (enExample)